LBA49 CANOPY-A: Phase III study of canakinumab (CAN) as adjuvant therapy in patients (pts) with completely resected non-small cell lung cancer (NSCLC)

E.B. Garon, S. Lu, Y. Goto, P.R. De Marchi, L. Paz-Ares, D.R. Spigel, M. Thomas, J.C-H. Yang, A. Ardizzoni, F. Barlesi, S. Khanna, C. Bossen, M. Carbini, A. Yovine, B.C. Cho